Evrosure
Expel Restenosis Rate
Cobalt Chromium Everolimus
Eluting Coronary Stent
The EvroSure contains Everolimus at a dose of 1.1 µg/mm² provides optimum anti-proliferation and endothelial regeneration, which in-turn assist to reduce Restenosiss.
Detail
For Unbeatable deliverbility which achieves:
Finely engineered elements of an expansive Cobalt Chromium L605 platform, enhances stent flexibility.
The blend of biodegradable PLLA and PLGA polymers with an Integrated Everolimus drug which release in approx 4 – weeks !! Ideal frame work for strength and compatibility.